Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
AKAkebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc. (AKBA)

NASDAQ Global Market · Currency in USD
$0.57 ▲ +0.00 (+0.84%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.56 ▼ -0.01 (-1.22%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$0.56
Open
$0.57
Day's Range
$0.56 – $0.60
52 Week Range
$0.54 – $3.20
Volume
10,991,053
Avg. Volume
6,727,927
Market Cap
$157.09M
Beta (5Y Monthly)
0.24
PE Ratio (TTM)
--
EPS (TTM)
-$0.11
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$1.00

Profile: Akebia Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
194
CEO
John Butler
Website
akebia.com

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.04 · Revenue est. $46.94M
DateEst.Actual
Aug 5, 2026-$0.04-$0.02Beat
May 7, 2026-$0.01-$0.03Miss
Feb 26, 2026-$0.03-$0.05Miss
Nov 10, 2025-$0.06$0.00Beat
Aug 7, 2025-$0.02$0.00Beat
May 8, 2025-$0.03$0.03Beat

Analyst view

Consensus price target
$1.00 ▲ +76.4%
Range $1.00 – $1.00
Rating: Buy
Buy 58% · Hold 33% · Sell 8%

Get free alerts on AKBA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.